Drug intelligence / Profile preview

FVH1

Development stage: Phase 1
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

FVH1 is a DNA-based influenza vaccine designed to prevent infection and disease caused by the H1N1 influenza virus. It utilizes DNA plasmids containing genes that express viral antigens. The vaccine aims to induce serum antibodies, secretory IgA antibodies, and/or cell-mediated immunity (CMI). Electroporation via the CELLECTRA® device is used to enhance the delivery and expression of the H1N1 influenza virus genes in the vaccine.

Targets

H1N1 (Influenza A virus H1N1)

Beyond the preview

Go deeper on FVH1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FVH1.

Explore the full profile